Friday, August 28, 2015

PeriRx, LLC Officially Launches SaliMark™ OSCC Test for Oral Squamous Cell Carcinoma




The SaliMark™ OSCC Salivary Diagnostic Test is Available Now 
Through Henry Schein, Patterson and Benco 

Broomall, PA – August 26,  2015 – PeriRx LLC, a premier developer of breakthrough, non-invasive, oral diagnostic technology, has officially launched SaliMark™ OSCC, an advanced molecular DNA test for the early detection of oral squamous cell carcinoma. The salivary test is now available from the online ordering systems of Henry Schein Dental, Patterson Dental and Benco Dental*.
“We’re very excited to bring this accurate, easy-to-use and non-invasive oral cancer screening tool to market,” said Stephen M. Swanick, CEO and founder of PeriRx, LLC. “The fact that these three leading dental suppliers all agreed to distribute SaliMark™ OSCC is a not only a testament to its efficacy but also their recognition of the test’s strong potential to lower the mortality rate of what the National Institute of Health says is the world’s sixth leading cause of cancer, which kills one American every hour of every day.”
Development of this simple-to-use, painless and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and pre-validation work conducted by Dr. David Wong of the University of California at Los Angeles.  What’s more, more than a decade of National Institute of Dental and Craniofacial Research and National Institute of Health-supported research make SaliMark™ OSCC the world’s most scientifically-validated molecular DNA biomarker test for oral squamous cell carcinoma.
The test is indicated for use when a visual oral examination (via naked eye or fluorescent device) detects a suspicious lesion or oral mucosal abnormality. SaliMark™ OSCC’s highly-accurate risk assessment capabilities can help the clinician make a more informed and confident decision on whether to refer the patient to a specialist for a biopsy.
“Although biopsies are the gold standard for determining pathology, they are invasive procedures that come back negative 90% of the time,” explained Swanick. “SaliMark™ will greatly improve the efficiency and accuracy of any oral cancer exam protocol.”
For more information about PeriRx, LLC or its SaliMark™ OSCC salivary test for oral squamous cell carcinoma, including scientific data, presentations, videos, peer-reviewed dental journal articles and product literature, visit www.PeriRx.com, call 610-544-3500 or send an email to info@PeriRx.com.
-more-
*Not yet approved for sale in the state of New York. Regulatory approval process is currently in progress. However, New York dentists who pre-register their practices online will be kept on file and notified immediately when SaliMark™ is approved for sale and use in their state.

About SaliMark™ OSCC
Development of this simple-to-use, painless and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and pre-validation work conducted by Dr. David Wong of the University of California at Los Angeles. The SaliMark™ OSCC test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer.  Recently, the SaliMark™ OSCC test underwent a PRoBE (prospective-specimen-collection, retrospective-blinded-evaluation) design study which is the most rigorous biomarker validation available. In addition, PeriRx successfully completed a validation of the mRNA markers at the University of Michigan, Michigan State University and the St. Johns Providence Health System in Detroit. 
About PeriRx LLC:
Based in Broomall, Pennsylvania, PeriRx, LLC is a premier developer of breakthrough, non-invasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.  
The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO and founder Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist. 

PeriRx, LLC obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through regulatory approval, and into commercialization.

Post a Comment